Arrowhead Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Arrowhead Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders to be held virtually on March 19, 2026, to vote on director elections, executive compensation, an incentive plan, and auditor ratification.
NASDAQ
Arrowhead Pharmaceuticals, Inc. announces its 2026 Annual Meeting of Stockholders, highlighting significant financial improvements, key regulatory approvals, and pipeline advancements.
NASDAQ
Arrowhead Pharmaceuticals appoints Douglas Ingram, CEO of Sarepta Therapeutics, to its Board of Directors, effective February 6, 2025, as part of an Investor Rights Agreement.
NASDAQ
Arrowhead Pharmaceuticals has filed a proxy statement with the SEC, signaling upcoming shareholder meetings and voting on company matters.
NASDAQ
DEF 14A: Arrowhead Pharmaceuticals Sets Date for 2025 Annual Stockholder Meeting, Outlines Key Proposals
Arrowhead Pharmaceuticals will hold its 2025 Annual Meeting of Stockholders virtually on March 12, 2025, to vote on director elections, executive compensation, auditor ratification, and other matters.
NASDAQ
Arrowhead Pharmaceuticals supplements its proxy statement to address concerns raised by ISS and Glass Lewis regarding the independence of director Dr. Douglass Given and announces changes to board committee assignments.